InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard(TM) Neuroprotection System

Stock Information for InspireMD Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InspireMD Inc.

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard(TM) Neuroprotection System
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.